BRPI1015014A2 - composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição - Google Patents
composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cogniçãoInfo
- Publication number
- BRPI1015014A2 BRPI1015014A2 BRPI1015014A BRPI1015014A BRPI1015014A2 BR PI1015014 A2 BRPI1015014 A2 BR PI1015014A2 BR PI1015014 A BRPI1015014 A BR PI1015014A BR PI1015014 A BRPI1015014 A BR PI1015014A BR PI1015014 A2 BRPI1015014 A2 BR PI1015014A2
- Authority
- BR
- Brazil
- Prior art keywords
- cognitive impairment
- indications
- compound
- pharmaceutical composition
- treating
- Prior art date
Links
- 208000028698 Cognitive impairment Diseases 0.000 title 2
- 208000010877 cognitive disease Diseases 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16940909P | 2009-04-15 | 2009-04-15 | |
| PCT/SE2010/050404 WO2010120237A1 (en) | 2009-04-15 | 2010-04-14 | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1015014A2 true BRPI1015014A2 (pt) | 2017-06-27 |
Family
ID=42981442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1015014A BRPI1015014A2 (pt) | 2009-04-15 | 2010-04-14 | composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8178529B2 (pt) |
| EP (1) | EP2419425A4 (pt) |
| JP (1) | JP2012524063A (pt) |
| KR (1) | KR20120013951A (pt) |
| CN (1) | CN102459252A (pt) |
| AR (1) | AR076300A1 (pt) |
| AU (1) | AU2010237100A1 (pt) |
| BR (1) | BRPI1015014A2 (pt) |
| CA (1) | CA2761064A1 (pt) |
| MX (1) | MX2011010732A (pt) |
| RU (1) | RU2011140238A (pt) |
| TW (1) | TW201040169A (pt) |
| UY (1) | UY32562A (pt) |
| WO (1) | WO2010120237A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| RU2011140238A (ru) * | 2009-04-15 | 2013-05-20 | Астразенека Аб | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера |
| EP2515654A4 (en) * | 2009-12-23 | 2013-04-24 | Map Pharmaceuticals Inc | NEW ERGOLINANALOGA |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| EP2723735A4 (en) | 2011-06-23 | 2015-02-18 | Map Pharmaceuticals Inc | NOVEL ANALOGUES OF FLUORO-ERGOLINE |
| AU2012355982A1 (en) | 2011-12-19 | 2014-07-10 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
| US8946420B2 (en) | 2011-12-21 | 2015-02-03 | Map Pharmaceuticals, Inc. | Neuromodulatory compounds |
| CN104822264A (zh) * | 2012-06-22 | 2015-08-05 | Map药物公司 | 新的卡麦角林衍生物 |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| KR102413579B1 (ko) | 2015-10-06 | 2022-06-28 | 주식회사 에이치엘클레무브 | 운전자 편의 장치 및 그의 타겟 추정 방법 |
| IL272988B (en) | 2017-09-08 | 2022-08-01 | Beigene Ltd | Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002503662A (ja) | 1998-02-17 | 2002-02-05 | テュラリク インコーポレイテッド | 抗ウイルス性ピリミジン誘導体 |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| BR0207096A (pt) | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| MXPA04004178A (es) | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| EP1554269A1 (en) | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| AU2004212421B2 (en) | 2003-02-07 | 2009-08-20 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| US7456190B2 (en) | 2003-03-13 | 2008-11-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| CA2533870A1 (en) | 2003-07-30 | 2005-02-10 | Shudong Wang | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| AU2006274733B2 (en) | 2005-07-30 | 2010-09-16 | Astrazeneca Ab | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
| CN101312977B (zh) * | 2005-09-22 | 2012-06-13 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作激酶调节剂的稠合杂环化合物 |
| CN101321531A (zh) | 2005-10-03 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途 |
| AR058073A1 (es) | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| WO2007138277A1 (en) | 2006-05-26 | 2007-12-06 | Astrazeneca Ab | 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
| TW200811169A (en) | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| EP2044058B1 (en) | 2006-06-21 | 2010-09-29 | AstraZeneca AB | Chemical compounds |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| TW200815418A (en) | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| EP2089023A2 (en) | 2006-11-02 | 2009-08-19 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
| WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| WO2009017455A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| WO2009017453A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| RU2011140238A (ru) * | 2009-04-15 | 2013-05-20 | Астразенека Аб | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера |
-
2010
- 2010-04-14 RU RU2011140238/04A patent/RU2011140238A/ru not_active Application Discontinuation
- 2010-04-14 MX MX2011010732A patent/MX2011010732A/es not_active Application Discontinuation
- 2010-04-14 TW TW099111649A patent/TW201040169A/zh unknown
- 2010-04-14 WO PCT/SE2010/050404 patent/WO2010120237A1/en not_active Ceased
- 2010-04-14 JP JP2012505856A patent/JP2012524063A/ja active Pending
- 2010-04-14 KR KR1020117024168A patent/KR20120013951A/ko not_active Withdrawn
- 2010-04-14 US US12/759,869 patent/US8178529B2/en not_active Expired - Fee Related
- 2010-04-14 UY UY0001032562A patent/UY32562A/es not_active Application Discontinuation
- 2010-04-14 CN CN2010800265500A patent/CN102459252A/zh active Pending
- 2010-04-14 EP EP10764741A patent/EP2419425A4/en not_active Withdrawn
- 2010-04-14 AU AU2010237100A patent/AU2010237100A1/en not_active Abandoned
- 2010-04-14 AR ARP100101250A patent/AR076300A1/es unknown
- 2010-04-14 BR BRPI1015014A patent/BRPI1015014A2/pt not_active IP Right Cessation
- 2010-04-14 CA CA2761064A patent/CA2761064A1/en not_active Abandoned
- 2010-04-14 US US13/264,529 patent/US20120077813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201040169A (en) | 2010-11-16 |
| KR20120013951A (ko) | 2012-02-15 |
| JP2012524063A (ja) | 2012-10-11 |
| MX2011010732A (es) | 2011-11-18 |
| WO2010120237A1 (en) | 2010-10-21 |
| EP2419425A4 (en) | 2012-08-29 |
| AR076300A1 (es) | 2011-06-01 |
| CA2761064A1 (en) | 2010-10-21 |
| EP2419425A1 (en) | 2012-02-22 |
| RU2011140238A (ru) | 2013-05-20 |
| US8178529B2 (en) | 2012-05-15 |
| US20100267723A1 (en) | 2010-10-21 |
| UY32562A (es) | 2010-11-30 |
| AU2010237100A1 (en) | 2011-10-27 |
| CN102459252A (zh) | 2012-05-16 |
| US20120077813A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
| BRPI1007477A2 (pt) | método, e, composição de tratamento de poço | |
| BRPI1010798A2 (pt) | fechamento, aparelho de retenção, e método de uso do mesmo | |
| BR112012013175A2 (pt) | 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2 | |
| BRPI1013559A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BRPI1014864A2 (pt) | "implante de processos espinhosos e métodos associados" | |
| BR112012006644A2 (pt) | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit | |
| BRPI0814941A2 (pt) | Composição de tratamentode semente, e, método de tratamento de semente. | |
| BRPI0918693A2 (pt) | dispositivos para amostragem e métodos para concentração de microorganismos | |
| BRPI0919288A2 (pt) | teriapia de combinação para tratamento de diabetes e condições relacionadas. | |
| BRPI1007996A2 (pt) | fluido de tratamento, e, método | |
| HUE049880T2 (hu) | Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére | |
| BR112012008048A2 (pt) | dispositivos eletrocrômicos, montagens que incorporam dispositivos eletrocrômicos, e/ou métodos de fabricação dos mesmos | |
| BR112012006640A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit | |
| BR112012006648A2 (pt) | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| FI20095553L (fi) | Jätteenkäsittelyjärjestelmä ja menetelmä | |
| PT2640375T (pt) | Método de tratamento da nefropatia induzida por contraste | |
| BRPI0917321A2 (pt) | prevenção, tratamento e diagnóstico de infecção por p. gingivalis | |
| BRPI0913739A2 (pt) | Composição líquida, método, e, uso de composição | |
| BR112012000025A2 (pt) | polipeptídos e processo de tratamento. | |
| BRPI0910161A2 (pt) | "método de esterilização de um objeto, e, aparelho de esterilização" | |
| BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |